GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Other Current Receivables

Accustem Sciences (Accustem Sciences) Other Current Receivables : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Other Current Receivables?

Accustem Sciences's Other Current Receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.


Accustem Sciences Other Current Receivables Historical Data

The historical data trend for Accustem Sciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Other Current Receivables Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23
Other Current Receivables
- -

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only - - - - -

Accustem Sciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Accustem Sciences Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Accustem Sciences (Accustem Sciences) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.